Environmental (atypical, opportunist, other) mycobacteria were first isolated nearly a century ago.
Pathogenic mycobacteria are clinically divided into three groups; the two major pathogens Mycobacterium tuberculosis and M leprae, the environmental species definitely associated with disease, and those rarely so.' The environmental mycobacteria are also known as atypical, opportunist, or mycobacteria other than M tuberculosis, none of which are completely satisfactory terms. There are four main types of disease caused by these opportunists: pulmonary disease, disseminated disease, which is particularly associated with HIV infection, lymph node disease in children, and local skin and soft tissue infections. ' We discuss the bacteriology of M fortuitum and present the clinico-pathological findings of a patient from whom the organism was isolated and proved fatal. 4 There is no universally accepted identification scheme for these organisms,5 with each laboratory relying on cultural characteristics (growth rate, temperature, pigment production), biochemical reactions, and antimicrobial sensitivity patterns. The table gives the diagnostic criteria for M fortuitum, which may also be phenotypically divided into three biovariantsnamely, fortuitum, pereg7inum, and a "third group" (unnamed).6 Thin layer chromatography of cell wall lipids, mycolic acid detection by gas liquid chromatography linked with mass spectrophotometry, and other sophisticated methods have also been described. 5 Dramatic outbreaks of M fortuitum prosthetic valve endocarditis and sternal wound infections aroused interest in these environmental mycobacteria.6 The incidence of this disease is unknown and depends on the opportunity for transmission and host susceptibility. These are unaffected by public health measures because person-to-person spread rarely, if ever, occurs. The route of entry is by inhalation of natural aerosols. Patients with impaired local lung defence mechanisms such as COAD, pneumoconiosis, and cystic fibrosis, or acquired and congenital immune defects are at risk, but patients without these risk factors have also been reported.79 The presentation of pulmonary infection includes bronchopneumonia, lung abscess, empyema, and a case of an asymptomatic enlarging pulmonary nodule has also been described.79 Our case report discusses an elderly male patient who had a long history of COAD requiring steroids and complicated by lung abscesses.
Mfortuitum pulmonary disease is diagnosed by isolation and identification of the organism but remains tendentious because of these organisms' ubiquity and their contaminating and colonising potential.'56 The American Thoracic Society's Diagnostic Standards and Classification of Tuberculosis and Other Mycobacterial Diseases (14th edition) lists the requirements for making the diagnosis: (1) evidence of disease, such as an infiltrate on chest radiograph and no other cause found; and (2) repeated isolation of multiple colonies of the same isolate, or from a closed lesion such as an abscess or biopsy material.
The natural history of pulmonary disease due to rapidly growing mycobacteria is poorly defined but seems to be progressive, not responding to conventional antituberculosis treatment. Recommended treatment includes initial amikacin-cefoxitin combination,4 but newer agents such as the fluoroquinolones (ciprofloxacin, ofloxacin)9 and carbapenems (imipenem)4 have been successfully used as well as surgery. Deaths seem to be rare but a fatal case reported by the Brompton Hospital London in 1984,8 together with others since and our report, confirm the real threat which M fortuitum poses, especially to patients with pulmonary disease or immune defects.
